(NASDAQ: CASI) Casi Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.29%.
Casi Pharmaceuticals's earnings in 2025 is -$46,890,000.On average, 1 Wall Street analyst forecast CASI's earnings for 2025 to be -$35,818,622, with the lowest CASI earnings forecast at -$35,818,622, and the highest CASI earnings forecast at -$35,818,622. On average, 1 Wall Street analyst forecast CASI's earnings for 2026 to be -$22,483,551, with the lowest CASI earnings forecast at -$22,483,551, and the highest CASI earnings forecast at -$22,483,551.
In 2027, CASI is forecast to generate -$21,863,315 in earnings, with the lowest earnings forecast at -$21,863,315 and the highest earnings forecast at -$21,863,315.